Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases

NCT03653546 is registered in ClinicalTrials.gov with Alpha Biopharma (Jiangsu) Co., Ltd. as lead sponsor.

NCT NCT03653546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03653546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Lead sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
October 29, 2018
Completion date
July 12, 2022
Enrollment
492 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, egfr gene mutation, non-small cell lung cancer